The blur is the finding
The semaglutide and tirzepatide pages each render a monthly figure inside an element carrying a seven-pixel blur filter, a rule that blocks text selection, and an attribute that hides the element from screen readers. Beside it sits an instruction to create a free account to view pricing. That is a deliberate treatment, not a rendering accident, and it is applied to the one number a reader came for.
It matters because presence in the page source is constantly mistaken for publication. This network has already shipped a review that quoted a table rendering nowhere. The test is whether a human being reading the page can read the fact, and here they cannot.
The same number is published to machines
The identical page carries schema.org product markup with the offer price in plain text. Search engines, shopping crawlers and answer engines are handed the figure directly. The visitor is handed a blur and a signup prompt.
There is no reading of that arrangement that favours the reader. If the price is not commercially sensitive enough to withhold from an indexing crawler, it is not sensitive enough to withhold from the person deciding whether to buy.
What the site does price openly
The pricing page is more forthcoming. It gives a floor for the peptide catalogue as a whole, a ceiling for the telehealth tier, and a flat figure for a provider consultation, and it states clearly that there is no subscription and nothing to cancel. Those are real disclosures and they are recorded here.
None of them is a GLP-1 price. The floor covers every peptide the service sells, most of which are not weight-management products at all. Filing a catalogue floor under semaglutide would attach a number to a molecule the seller never attached it to, which is precisely the error this roster refuses to make.
Coverage is broad, sourcing is thin
PeRx states that it serves all fifty states by telehealth and ships nationwide, which removes the most common reason a promising seller turns out to be unavailable. Shipping is described as overnight and supplies as included.
Against that, the compounding pharmacies are described only by licensing class and never named, and no individual prescribing clinician or medical director appears anywhere we read. For a compounded medication, the pharmacy name is the disclosure that matters most, and it is missing alongside the price.
PeRx's published pricing
| Medication | Price | Verified |
|---|
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 283 providers reviewed here are paid partners today; the other 279 are not. See how this works.
See PeRx's current price →Good fit if
- Readers who want nationwide telehealth availability and are willing to create an account before seeing a number.
- Patients ordering peptides other than GLP-1 medications, where the catalogue range and the consultation fee are stated openly.
- Anyone who wants the absence of a subscription stated explicitly rather than inferred.
- Readers comparing the shape of a peptide catalogue rather than a specific weight-management figure.
Look elsewhere if
- Anyone comparing GLP-1 prices. The figure exists on the page and is deliberately unreadable.
- Readers who need the compounding pharmacy named before they will take a compounded medication.
- Patients who want a named prescribing clinician or medical director.
- Anyone who considers an account wall in front of a price a reason to look elsewhere, which is a defensible position here.
How this review was verified
- Read the pricing page and both GLP-1 drug pages at their source URLs, and fetched the raw markup of the semaglutide page to see how the figure is rendered.
- Confirmed the price element carries a blur filter, a selection block and an attribute hiding it from assistive technology, and that the accompanying text asks the reader to create an account.
- Confirmed the same page publishes the figure in machine-readable product markup, where no such treatment applies.
- Recorded no price row on this basis, and recorded the catalogue floor and the consultation fee as what they are rather than filing either under a compound.
- Pulled all 3,677 rows of the FDA warning-letter table and filtered them locally with a known-positive and a nonsense-string control in the same run; no letter found.